On Invalid Date, Standard Biotools (NASDAQ: LAB) reported Q1 2023 earnings per share (EPS) of -$0.21, up 78.79% year over year. Total Standard Biotools earnings for the quarter were -$16.84 million. In the same quarter last year, Standard Biotools's earnings per share (EPS) was -$0.99.
As of Q2 2023, Standard Biotools's earnings has grown year over year. Standard Biotools's earnings in the past year totalled -$130.65 million.
What was LAB's revenue last quarter?
On Invalid Date, Standard Biotools (NASDAQ: LAB) reported Q1 2023 revenue of $25.12 million up 5.23% year over year. In the same quarter last year, Standard Biotools's revenue was $26.50 million.
What was LAB's revenue growth in the past year?
As of Q2 2023, Standard Biotools's revenue has grown -22.31% year over year. This is 28.24 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 5.94%. Standard Biotools's revenue in the past year totalled $96.56 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.